National Institute of Allergy and Infectious Diseases

ClinicalRM awarded NIH contract

Monday, September 16, 2013 08:52 AM

CRO Clinical Research Management was awarded a contract by the Department of Health and Human Services, NIH, Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). The intent of the award is to provide a broad spectrum of services for the design and conduct of phase I-IV clinical trials and clinical studies focused on the screening, diagnosis, treatment, prevention and control of sexually transmitted infections within the Sexually Transmitted Infections Clinical Trials Group (STI CTG) Program.

More... »

Enanta receives additional $9.2m funding from NIAID

Wednesday, September 4, 2013 03:54 PM

The National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, has agreed to provide additional funding of $9.2 million to its existing contract with Enanta Pharmaceuticals, an R&D-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, to fund preclinical and early clinical development for a new class of bridged bicyclic antibiotics known as Bicyclolides.

More... »

Inovio, U.S. Army receive $3.5M biodefense grant for mass vaccination device

Friday, April 12, 2013 11:22 AM

Inovio Pharmaceuticals has been selected to receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.

More... »

Altravax awarded $1.2M to advance dengue vaccine and hep B therapeutic

Friday, January 11, 2013 11:13 AM

Altravax, a privately held biopharmaceutical company based in Fargo, N.D., has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH's National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax's two lead commercial programs.

More... »

ADi awarded $2.5M SBIR grant to identify malaria protection biomarkers

Monday, August 13, 2012 10:13 AM

Antigen Discovery (ADi), a biotech based in Irvine, Calif., has received a phase II Small Business Innovation and Research (SBIR) award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

More... »

SRI International to develop bioadhesive gel for HIV and HSV

Monday, July 30, 2012 10:09 AM

SRI International, a global nonprofit research institute, has received a grant from the National Institute of Allergy and Infectious Diseases (NIAID) that will support the development of a topical microbicide gel for combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

More... »

Emergent receives NIAID grant for TB vaccine

Friday, March 23, 2012 01:06 PM

Emergent BioSolutions has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of MVA85A, a candidate vaccine against tuberculosis (TB).

More... »

Soligenix demonstrates proof of concept with vaccine technology

Tuesday, February 7, 2012 10:49 AM

Soligenix, a development-stage biopharmaceutical company, has released results from pre-clinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

More... »

NIH to join multi-center trial of new tuberculosis vaccine

Tuesday, February 7, 2012 07:34 AM

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), has joined a phase II proof-of-concept clinical trial of a tuberculosis (TB) vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

More... »

Giant leap for HIV cure

Wednesday, January 11, 2012 11:09 AM

After 30 years of unsuccessful attempts, an HIV vaccine may be within reach. That’s what scientists at Crucell NV of the Netherlands (a subsidiary of Johnson & Johnson) are saying.

More... »